Table 3.

Examples of active “hybrid” trials matching patients to therapies based on molecular profiles

Program nameLead organizationDesignHistologyIndication# Expected to accruePrimary outcome measure(s)Clinicaltrials.gov identifier
NCI-MATCHNCINRAdvanced solid tumors and lymphomasMetastatic3,000ORRNCT02465060
ECOG-ACRIN and NCTN
NCI-MPACTNCIRAdvanced solid tumorsMetastatic700ORR or PFSNCT01827384

Abbreviations: NR, nonrandomized; ORR, overall response rate; PFS, progression-free survival; R, randomized.